Trial Profile
Prospective, Open-label, Multicenter Phase 3b Study to Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Simoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms NuPreviq
- Sponsors Octapharma
- 31 Oct 2023 According to Octapharma media release, data from the study were presented in the European Journal of Haematology.
- 31 Oct 2023 Results of Indirect comparison from a matching-adjusted indirect comparison (MAIC) of Nuwiq (simoctocog alfa) versus extended half-life recombinant factor VIII (rFVIII) concentrates in haemophilia A patients undergoing personalised prophylaxis published in the Media Release
- 06 Jun 2023 According to Octapharma media release, data from this study will be presented at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) on June 24-28, 2023, in Montreal, Canada.